Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers
These findings underscore the critical role of antitumor immunity, particularly CD8<sup>+</sup>T cell activity, in the efficacy of tipifarnib alone and in combination with alpelisib. The triple combination of tipifarnib, alpelisib, and anti-PD1 treatment showed superior antitumor activity and extended survival in preclinical models, suggesting its potential as a therapeutic strategy for HNSCC patients with HRAS- and PIK3CA-mutation.
Authors
- Sooraj Mathukkada (ORCID: https://orcid.org/0000-0002-0210-2399)
- Monica Wainer (ORCID: https://orcid.org/0000-0002-7281-181X)
- Manu Prasad (ORCID: https://orcid.org/0000-0001-7690-3511)
- Sankar Jagadeeshan (ORCID: https://orcid.org/0000-0002-3778-8757)
- Francis Burrows (ORCID: https://orcid.org/0000-0003-0274-4911)
- Moshe Elkabets (ORCID: https://orcid.org/0000-0003-3634-9098)
- Gloria H. Su (ORCID: https://orcid.org/0000-0002-5158-6019)
- Noam Erez (ORCID: https://orcid.org/0000-0001-5241-8028)
- Irit Allon (ORCID: https://orcid.org/0000-0003-1861-0782)
- Ari J. Rosenberg (ORCID: https://orcid.org/0000-0001-5908-0939)
- Luc G.T. Morris (ORCID: https://orcid.org/0000-0002-4417-2280)
- Linda Kessler (ORCID: https://orcid.org/0000-0002-8677-3252)
- Raghda Abu Shareb
- Divyasree Marripati (ORCID: https://orcid.org/0000-0002-5695-8838)
- Liju Vijaya Steltar Belsamma
- Hai Wang (ORCID: https://orcid.org/0000-0002-1292-998X)
- Dinesh Babu Manikandan (ORCID: https://orcid.org/0000-0003-0605-9946)
- Amit Geva
- Danielle Raviv
Institutions
- Ben-Gurion University of the Negev (IL)
- Memorial Sloan Kettering Cancer Center (US)
- Columbia University Irving Medical Center (US)
- Barzilai Medical Center (IL)
- University of Chicago (US)
- National Center for Nanoscience and Technology (CN)
- Kura Oncology (United States) (US)
Publication Details
- Journal
- Neoplasia
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1016/j.neo.2025.101157
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- United States - Israel Binational Science Foundation
- Ministry of Science, Technology and Space
- Israel Science Foundation